Condition
Refractory Pediatric AML
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Unknown1
Recruiting1
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07156435Phase 1Recruiting
Vyxeos® With Clofarabine for Pediatric AML
NCT05622591Phase 1Withdrawn
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
NCT02638428Phase 2Unknown
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Showing all 3 trials